SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GitLab, Inc. engages in the intelligent DevSecOps platform for software innovation. The firm enables organizations to increase developer productivity, improve operational efficiency, reduce security and compliance risk, and accelerate digital transformation. The company was founded by Dmitriy Zaporozhets and Sid Sijbrandij in 2011 and is headquartered in San Francisco, CA.

Gitlab Inc - Ordinary Shares - Class A

Gitlab Inc

Gitlab is trending following its earnings report, which showed a beat on Q4 revenue and non-GAAP EPS but delivered weaker-than-expected forward guidance. This has ignited a fierce debate in the community, with concerns over slowing growth and AI competition clashing against arguments for the company's strong fundamentals, buyback program, and AI integration tailwinds.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with Knife ($CAW) is generating strong community buzz, frequently discussed as a multi-chain meme coin with an organic, decentralized approach and a deflationary burning mechanism, further fueled by its growing presence on platforms like Coinbase and Base.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending at multi-year highs amid intense anticipation for its pivotal Phase 3 REGAL trial results for GPS in AML, with strong community conviction in a groundbreaking outcome driving discussions of a potential buyout and a significant short squeeze.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending amidst community debate over its persistently delayed earnings report date and a recently retracted Pentagon listing linking it to China's military. While many view the stock as oversold and undervalued with promising AI advancements, others remain cautious of ongoing geopolitical and regulatory uncertainties impacting the Chinese tech giant.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle (CRCL) is experiencing significant momentum after its strong Q4 earnings highlighted robust growth in USDC circulation and on-chain transaction volume, with the community actively discussing its pivotal role as a foundational payment standard for AI agentic commerce, driving its rally as a key stablecoin infrastructure play.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending due to significant market volatility, as investors weigh strong fundamental tailwinds from soaring AI-driven memory demand and recent analyst upgrades against broader market contagion from geopolitical tensions impacting major South Korean chip competitors. This has created a polarized discussion, with bulls viewing the dip as a prime buying opportunity given Micron's robust HBM sales and upcoming earnings, while bears anticipate further correction amidst macro fears and profit-taking.

BlackRock Institutional Trust Company N.A. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

The iShares MSCI South Korea ETF (EWY) is plummeting and experiencing market halts amid escalating Middle East tensions and surging oil prices, fueling widespread fear selling and deleveraging in what many describe as a "crowded retail trade." Conversely, some community members are actively discussing this as a strong "buy the dip" opportunity, citing resilient fundamentals for its key memory/AI chip holdings like Samsung and SK Hynix.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd is trending amid intense community debate, as a puzzling sell-off starkly contrasts with soaring crude oil prices and escalating Middle East tensions, prompting discussion of market manipulation, dilution, or a significant shakeout before a potential rally.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending as escalating Middle East tensions, including Iran's threats to the Strait of Hormuz, spark concerns over global oil supply and trigger a sharp sell-off across Asian markets, heavily impacting the semiconductor sector. Despite international market turmoil, traders are debating the Nasdaq's unusual intraday resilience, questioning if it can withstand geopolitical pressures or if a deeper correction is imminent.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSM is hitting new highs, driven by stellar January revenue growth and its 2nm capacity being fully booked by top-tier clients, solidifying its indispensable role in the AI chip supercycle. The community widely views the company as the foundational "picks and shovels" leader despite persistent geopolitical uncertainties.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company announced a 1-for-25 reverse stock split.</li><li>The split takes effect Thursday, with split-adjusted trading Friday, reducing outstanding shares to about 1.1 million from 27.8 million.</li><li>The move comes amid continued progress on AD04, with Phase 3 planning completed.</li></ul>Shares of Adial Pharmaceuticals Inc.&nbsp;cratered over 20% in after-hours trading on Tuesday after the company announced a 1-for-25 reverse stock split to restore compliance with Nasdaq’s minimum bid price requirement.<h2 class="st-heading-2">ADIL Reverse Stock Split&nbsp;</h2>Adial said the reverse split will take effect Thursday, with the stock set to begin trading on a split-adjusted basis on Friday. This will reduce outstanding common shares to nearly 1.1 million from about 27.8 million, while shareholder ownership percentages will remain unchanged, apart from the treatment of fractional shares. The company added that proportional adjustments will be made to outstanding equity awards and warrants, including exercise prices.Adial said the reverse split is intended to bring the company back into compliance with Nasdaq’s $1 minimum bid price rule, a requirement for maintaining its listing.<h2 class="st-heading-2">AD04 Development In Focus</h2>The reverse split comes as Adial continues to advance AD04, its genetically targeted serotonin-3 receptor antagonist for the treatment of Alcohol Use Disorder, with a focus on heavy drinking patients and select genotypes.The company has advanced Phase 3 trial design and planning, drawing on analyses of historical clinical data that identified genotype-defined subgroups more likely to benefit from the therapy.&nbsp;On the regulatory front, Adial completed its End-of-Phase-2 discussions with the U.S. Food and Drug Administration (FDA), saying the agency provided input on the Phase 3 adaptive trial design and the broader clinical program. The company said the discussions covered key elements such as patient population, endpoints, dosing, and confirmation of biomarker-positive and biomarker-negative groups, including a focus on the AG+ genotype, and were later formalized through final FDA meeting minutes.Adial has also worked to strengthen intellectual property protection for AD04, saying an international patent application covering the program has been published and, if granted, is expected to protect its core assets through at least 2045.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment was ‘bearish’ amid ‘normal’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/adil_ss_png_001d17e3e8.webp" alt="adil ss.png" width="975" height="148"><figcaption>ADIL sentiment and message volume as of February 3 | Source: Stocktwits</figcaption></figure>One user said the market reaction appeared overly short-term focused, adding that near-term share price moves mattered less to them, as they viewed Adial as a “long-term story” and said the company’s underlying clinical progress has been moving well.<stembedurl>https://stocktwits.com/Prazzclatt/message/643712705</stembedurl>Another user said, “more dilution will follow after min price bid met. It will be voted on at end of the month. This will likely be below $1 again by March.”<stembedurl>https://stocktwits.com/StayPresent/message/643885507</stembedurl><a href="https://stocktwits.com/symbol/ADIL">ADIL’s stock</a> has declined 75% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

ADIL’s stock has declined 75% over the past 12 months.

Why Did Adial Pharmaceuticals Stock Plunge Over 20% After Hours Today?

The reverse split is intended to bring the company back into compliance with Nasdaq’s $1 minimum bid price rule.

Equity

Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year?

Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.

All You Need to Know About Adial Pharmaceuticals (ADIL) Rating Upgrade to Buy

Adial Pharmaceuticals (ADIL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Adial Pharmaceuticals (ADIL) Upgraded to Strong Buy: Here's Why

Adial Pharmaceuticals (ADIL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Retail investors are buzzing about Adial Pharmaceuticals after the company announced the issuance of a key U.S. patent, which strengthens its strategy in precision medicine for addiction treatment.&nbsp;The announcement sent shares soaring to $0.78 during Thursday’s session — the stock’s highest level since February.The patent, officially granted on April 15 by the United States Patent and Trademark Office (USPTO), covers a novel method of treating alcohol- and opioid-related disorders using Adial’s investigational therapy, AD04, in patients with specific genetic markers.The company’s approach positions AD04 as a targeted therapy — not a one-size-fits-all solution — marking a significant step forward in the personalized treatment of addiction.The newly issued patent outlines the administration of AD04 to individuals with serotonin-related gene variations, including genotypes of HTR3A, HTR3B, and SLC6A4, such as the LL genotype of 5-HTTLPR, along with SNPs rs1150226, rs17614942, and rs1176713.&nbsp;The claims also include dosing regimens customized to these genetic profiles — a key component of Adial’s precision medicine approach.In addition to alcohol use disorder (AUD), the patent extends to a wide range of related conditions, including alcohol-induced anxiety, bipolar disorder, sexual dysfunction, sleep disturbances, gambling disorder, and alcohol withdrawal.&nbsp;The retail trading community was quick to react on Stocktwits.&nbsp;Sentiment&nbsp;flipped to ‘extremely bullish’ amid ‘extremely high’ message volume, underscoring strong retail engagement.&nbsp;One user said, “Great news today sent it flying,” while another predicted the stock could jump 50% to 100% in after-hours or the following day, calling the initial 11% gain “a bargain.”<stembedurl>https://stocktwits.com/GracebyFaith/message/613308669</stembedurl><stembedurl>https://stocktwits.com/KING_CRUSH/message/613278365</stembedurl>That retail enthusiasm is complemented by positive analyst coverage. According to data from Koyfin, two of the three analysts covering Adial currently rate the stock a ‘Buy,’ with the third assigning a ‘Hold.’&nbsp;Notably, no analysts have issued ‘Sell’ or ‘Strong Sell’ ratings.Despite Thursday’s spike, Adial shares remain down 26.4% year-to-date, underperforming the broader market. In comparison, the Nasdaq is down 1.7%, while the Dow and S&amp;P 500 have declined 3.9% and 4.5%, respectively, over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Dirty needles are collected by outreach workers with St. Ann’s Corner of Harm Reduction as they participate in a weekly needle clean-up at a Bronx park that drug users often use on April 23, 2025 in New York City. (Photo by Spencer Platt/Getty Images)

Retail Traders Flock To Adial Pharma After Patent News Sends Shares Soaring

Adial Pharmaceuticals jumped to its highest level since February after receiving a U.S. patent for its precision medicine approach to treating addiction. The patent supports the use of AD04 in patients with specific genetic markers.

Adial Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment or prevention of addiction and related disorders. It offers the AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson and William B. Stilley, III in November 2010 and is headquartered in Glen Allen, VA.

ADIL
Adial Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest ADIL News

ADILAdial Pharmaceuticals Inc